-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On August 12, Sihuan Biological issued an announcement stating that its subsidiary Xuanzhu Biological's application for a phase III clinical trial of Pirosinil (Birociclib, XZP-3287), a class 1 innovative drug under development, was approved by the China Food and Drug Administration
Breast cancer is one of the highest incidence of malignant tumors in the world.
The results of the clinical phase I study showed that as a new structure of CDK4/6 inhibitor, Pirosinib is expected to overcome the resistance problem of endocrine therapy in HR+ breast cancer patients; at the same time, Pirosinib is a single agent for advanced breasts that have failed multi-line therapy.
At present, there are 3 domestic companies that have approved the listing of CDK4/6 inhibitor drugs, namely Eli Lilly, Pfizer and Qilu Pharmaceuticals
Source: PharmaGo
In 2020, the annual sales of CDK4/6 products on the market will exceed 7 billion U.